News

FDA-Approved Indication for KEYTRUDA® (pembrolizumab) Announced

Posted on 11.9.2018

Merck is pleased to announce that KEYTRUDA in combination with carboplatin and either paclitaxel or nab-paclitaxel has been approved by the FDA for the first-line treatment of patients with metastatic squamous NSCLC.

KEYTRUDA is also indicated in combination with pemetrexed … Read More

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

Posted on 11.5.2018

Pfizer Inc. (NYSE:PFE) announced 11-5-18 that the U.S. Food and Drug Administration (FDA) has approved LORBRENA® [lor-BREN-ah] (lorlatinib), a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) whose disease … Read More

CMS releases the final rule for the Medicare Physician Fee Schedule Changes for 2019.

Posted on 11.3.2018

The Centers for Medicare & Medicaid Services (CMS) released the final rule for the Medicare Physician Fee Schedule (MPFS) and Quality Payment Program (QPP) outlining reimbursement changes for 2019. CMS estimates that the overall impact will be a one percent … Read More

Pfizer announced the FDA approval of TALZENNA® (talazoparib) on October 16, 2018.

Posted on 11.1.2018

Pfizer announced the FDA approval of TALZENNA® (talazoparib) on October 16, 2018. The following information is for your review:

Prescribing Information: click hereRead More

American Society of Clinical Oncology to submit comments on Part B Payment Model Proposal

Posted on 11.1.2018

ASCO shares the Administration’s goal of achieving lower drug costs but is concerned about some aspects of the proposal. ASCO is analyzing the proposal to determine the impact on patient care and practices. The society will respond to the Administration’s … Read More

CMS Takes Action to Modernize Medicare Home Health

Posted on 11.1.2018

On October 31, CMS finalized significant changes to the Home Health Prospective Payment
System (PPS) to strengthen and modernize Medicare. Specifically, CMS made changes to
improve access to solutions via remote patient monitoring technology, updated payments for
home health care … Read More

AstraZeneca announces FDA approval of LUMOXITITM for the treatment of certain adult patients

Posted on 9.18.2018

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has approved LUMOXITITM (moxetumomab pasudotox-tdfk), a first-in-class CD22-directed cytotoxin, for the treatment of adult patients with relapsed or refractory hairy … Read More

FDA Approves Expanded Label for Merck’s KEYTRUDA®

Posted on 8.29.2018

FDA Approves Expanded Label for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy for First-Line Treatment of Patients with Metastatic Nonsquamous NSCLC, with No EGFR or ALK Genomic Tumor Aberrations
Approval Based on Results of KEYNOTE-189, Where … Read More

2019 Physician Fee Schedule Proposed Rule

Posted on 8.27.2018
The  2019 Medicare Physician Fee Schedule Proposed Rule with comment period  was placed on display at the Federal Register on July 12, 2018. This proposed rule updates payment policies, payment rates, and other provisions for services furnished under the Medicare
Read More

Opdivo® (nivolumab) Receives FDA Approval for Certain Patients with Previously Treated Small Cell Lung Cancer

Posted on 8.17.2018

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as the First New Medication in Nearly 20 Years for Certain Patients with Previously Treated Small Cell Lung Cancer

(BMS) Aug 17, 2018 – Bristol-Myers Squibb Company today announced that Opdivo (nivolumab) … Read More